LAB282: Accelerating Oxford drug discovery
LAB282 is an exciting £13m public private partnership between the University, Oxford Sciences Innovation, and the international drug discovery company Evotec AG, to accelerate drug discovery in Oxford. There is currently a lack of funding to help translate basic research in disease-related biological pathways into focused drug discovery programmes. LAB282 seeks to address this unmet need, to stimulate the formation of new projects and companies to develop ground-breaking therapies, and ultimately to generate patient benefit. LAB282 projects will be sourced from across the research activities in the University of Oxford, from any disease area and will include all therapeutic modalities. Successful applicants will partner with Evotec to gain access to their industry leading drug discovery services through an award based scheme. This talk will detail the LAB282 initiative and how to apply.
Date: 2 November 2017, 11:00 (Thursday, 4th week, Michaelmas 2017)
Venue: Dorothy Crowfoot Hodgkin Building, off South Parks Road OX1 3QU
Venue Details: Main Seminar Room
Speaker: Dr Thomas Hanke (, LAB282 Expert in Residence, and Head of Academic Liaison, Evotec AG)
Organising department: Department of Biochemistry
Organiser: Professor Mark Howarth (Department of Biochemistry)
Organiser contact email address: mark.howarth@bioch.ox.ac.uk
Host: Professor Mark Howarth (Department of Biochemistry)
Part of: Seminar
Booking required?: Not required
Audience: Members of the University only
Editor: Sarah-Jane Scard